Multiomics for the identification of genetic predictors of survival in patients with sepsis
Details
Acronym: m-{omics}SEP
Partners:
- Unidad de Investigación del Hospital Universitario Ntra. Sra. de Candelaria
- Instituto Tecnológico y de Energías Renovables (ITER) – project’s coordinator
Duration: 2018-2020 (3 years)
Budget: 99.200,00 €
Financing:
Strategic Action in Health 2013-2016
State Program for Research Oriented to the Challenges of Society
State Plan for Scientific and Technical Research and Innovation 2013-2016
Instituto de Salud Carlos III
Ministry of Economy, Industry and Competitiveness (MINECO)
Overview of the project
This project, led by the University Hospital Nuestra Señora de Candelaria affiliated with the Biomedical Research Networking Center for Respiratory Diseases (CIBERES), through the Canary Islands Foundation for Health Research (FUNCANIS), in collaboration with other academic and healthcare institutions (University of Valencia; University Hospital La Paz, Madrid; University Hospital Río Hortega, Valladolid), aims to identify genetic factors of survival in sepsis and characterize early lung dysbiosis associated with the risk of death.
The collaboration of ITER in this project will facilitate the first genomic survival association study of sepsis in Spain by analyzing more than 8 million genetic variants in DNA samples from diagnosed adult patients. These data will also be used to validate the relationship between mitochondrial DNA copy number in blood and survival. The scientific-technical team from ITER’s Genomics area collaborates in this initiative using high-throughput massive sequencing methods, enabling the analysis of sepsis patient exomes for potential causal genes for the first time. The project will also delve into the characterization of early lung dysbiosis and its prognostic value in these patients.
The results of this project will identify essential genetic survival factors to understand sepsis pathophysiology, propose therapeutic targets, and improve the prediction of risk of death in these patients.
In addition to the disease team, ITER participates as a collaborator with various national institutions, including the aforementioned University Hospital Nuestra Señora de Candelaria, the University of Valencia, University Hospital La Paz (Madrid), and University Hospital Río Hortega (Valladolid), in a project funded under the 2017 Strategic Action in Health of the Carlos III Health Institute. This project aims to identify genetic factors involved in sepsis survival from a multiomic perspective, including exome sequencing and characterization of early changes in the pulmonary microbiome associated with the risk of death from this disease. This collaboration adds to the existing collaboration in the field of respiratory diseases to decipher the genetic causes of the development and progression of idiopathic pulmonary fibrosis.
Objective
.Sepsis remains a leading cause of mortality in Intensive Care Units. Its treatment lacks targeted therapies, and the usual alternatives for risk stratification are not standardized, resulting in an inability to predict patient mortality risk accurately, thus preventing reductions in mortality rates.”
